Globus Medical Q3 Earnings Forecast Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Research analysts at Zacks Research upped their Q3 2026 earnings estimates for Globus Medical in a note issued to investors on Thursday, October 29th. Zacks Research analyst Team now forecasts that the medical device company will post earnings of $1.19 per share for the quarter, up from their prior estimate of $1.18. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share. Zacks Research also issued estimates for Globus Medical’s FY2026 earnings at $4.98 EPS, Q1 2027 earnings at $1.14 EPS, Q2 2027 earnings at $1.34 EPS, FY2027 earnings at $5.07 EPS, Q2 2028 earnings at $1.47 EPS and FY2028 earnings at $5.89 EPS.

A number of other analysts have also commented on the stock. Royal Bank Of Canada lowered their target price on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Wells Fargo & Company decreased their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, Truist Financial lowered their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.46.

Globus Medical Stock Up 2.1%

Shares of GMED stock opened at $82.95 on Friday. Globus Medical has a 12 month low of $59.51 and a 12 month high of $101.40. The stock has a 50-day moving average price of $77.79 and a 200 day moving average price of $83.57. The firm has a market cap of $11.14 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 1.31 and a beta of 0.96.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors have recently modified their holdings of GMED. Janus Henderson Group PLC lifted its stake in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP grew its position in Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Dimensional Fund Advisors LP grew its position in Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares during the period. The Manufacturers Life Insurance Company increased its stake in Globus Medical by 2.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock valued at $97,557,000 after purchasing an additional 30,412 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock valued at $78,656,000 after purchasing an additional 471,875 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Buying and Selling at Globus Medical

In other news, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the director owned 15,000 shares in the company, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.